OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities

OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia
August 15, 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
September 19, 2018

1.Date of the event: Sep 5, 2018
2.Time: 14:30:00 CST
3.Location:Masterlink Securities (Address: No.97-11, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, Taiwan)
4.Summary: OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities
5.Any other matters that need to be specified: None
Please refer to MOPS for detail financial information regarding the event.